

Life Saving Drugs Program (LSDP) Initial application form for subsidised treatment for Late-Infantile Onset Batten Disease (CLN2 disease)

About this Program

The LSDP is administered by the Department of Health and Aged Care (the Department). Access to treatment for CLN2 disease is provided in accordance with the *Guidelines for the treatment of CLN2 disease through the Life Saving Drugs Program* (the Guidelines).

It is recommended that you read the Guidelines before completing this application form.

Patient Administration

Patient applications are processed within 30 calendar days of the receipt of the complete data package to support the application.

Should subsidised treatment be approved, it is the responsibility of the treating physician to ensure that the patient/patient's family is informed of:

- a) Treatment arrangements, including approved dose
- b) The requirement to submit a reapplication for subsidised treatment through the LSDP by 1 May each year to request ongoing subsidised treatment
- c) The requirement to notify the LSDP in writing immediately if a change to the treatment location is planned and
- d) The requirement to notify the LSDP in writing immediately if treatment is ceased.

Filling in this form

The application form must be filled out by a treating physician with relevant specialist registration, with the consent of the patient or parent/guardian. The patient or their parent/guardian is required to sign the application form to provide consent to the Department to collect personal information.

Please complete electronically, print and sign; or Use black or blue pen and print in BLOCK LETTERS.

All pages of this application form must be completed and submitted. Incomplete applications will not be processed.

Information Requirements

All assessments to support eligibility, excluding genetic testing, must have been undertaken within the 12 months prior to the date of application.

For more information

For more information go to the LSDP website: www.health.gov.au/lsdp

If you need assistance completing this form, or for more information call **(02) 6289 2336**, Monday to Friday, between 9.00 am and 5.00 pm, Australian Eastern Time.

Submitting your form

Send the completed application form and all relevant attachments:

By email to: lsdp@health.gov.au

By fax to: (02) 6289 8537

Page 1 of 4 Version date: October 2024

Privacy notice

The Department is collecting personal information about the patient identified on this application form to process this patient's initial application to receive subsidised treatment through the LSDP. If subsidised treatment through the LSDP is approved, the Department will continue to collect personal information about this patient in order to process a confirmation of ongoing eligibility.

If all of the personal information required is not provided, the Department will not be able to process the initial application to confirm eligibility to receive subsidised treatment through the LSDP.

The Department will disclose personal information to this patient's treating physician, pharmacists, clinic nurses and other health care professionals who may be involved in the administration of this patient's treatment.

The Department will disclose this patient's personal information including Medicare number to Services Australia in order to confirm Medicare eligibility and permanent Australian residency requirements.

'De-identified' personal information will be used for the purpose of the evaluation of the LSDP, which may include the provision of these data to third parties contracted by the Department for this purpose.

The Department has an Australian Privacy Principles (APP) privacy policy which can be read at

https://www.health.gov.au/resources/publications/privacy-policy

The Department can be contacted by telephone on (02) 6289 1555 or freecall 1800 020 103 or by using the online enquiries form at www.health.gov.au

A copy of the APP privacy policy can be obtained by contacting the Department using the contact details set out above. The APP privacy policy contains information about:

- how to access personal information the Department holds and how to seek correction of it; and
- how to complain about a breach of the APP.

The Department is unlikely to disclose personal information to overseas recipients.

Patient's details

Medicare card number					
			Ref no.		
Mr Mrs	Miss	Ms	Other		
Given Name					
Family Name					
Residential address					
Suburb		State	Post Code		
Subuib			r ost code		
Date of Birth					

Consent to collection of sensitive information for treatment and after cessation of treatment

I consent to the Department collecting genetic and health information about the patient identified on this application form for the purpose indicated above.

I consent to the Department requesting and obtaining sensitive information and supplemental information from my treating physician regarding the reason(s) for ceasing treatment including cause of death, if applicable.

If this information is not able to be obtained from my treating physician, I consent to the Department requesting and obtaining this information from other Government agencies and non-government organisations.

The information collected in this process is for the purpose of determining the cause of discontinuation of subsidised treatment.

Continuing eligibility for subsidised treatment for CLN2 disease through the LSDP

I understand that:

- if I/the patient fail to comply with the associated monitoring and assessment requirements, without an acceptable reason to do so, I/the patient will no longer be eligible to receive subsidised treatment through the LSDP.
- if treatment does not result in a clinically meaningful effect, subsidised treatment through the LSDP may be discontinued.

Signature			
Patient	Parent	Guardian 🗌	(tick one only)
Full name (print in BLOCK LETTERS)			
Date			

Page 2 of 4 Version date: October 2024

Treating physician's details	Pharmacist's details
Prescriber number	Given name
Circum manus	Family name
Given name	, L
	Work phone number
Family name	, <u> </u>
	Email address
Work phone number	
	Hospital/Department
Mobile phone number	
	Delivery address (for LSDP stock)
Email address	
	Suburb State Post Code
Hospital/Department	Sate Test sout
Postal address	Secondary pharmacy contact's details
	Given name
Suburb State Post Code	
State 1 set sea	Family name
Clinic nurse details	Work phone number
Given name	
GIVEN HAME	Email address
Equily name]
Family name]
TAY 1 1 1	Dosing details
Work phone number	Generic name of medicine requested:
Email address	Patient's age: Patient's weight:
	kg
Hospital/Department	Refer to CLN2 guidelines for age based dosage.
	Dosage of medicine requested: (every other week)
Postal address	mg vials
Suburb State Post Code	

Eligibility confirmation checklist

To qualify for LSDP subsidised treatment, all of the following initial eligibility requirements must be met.

The treating physician must initial the box to confirm that the requirement is met.

- 1. Diagnosis of CLN2 disease has been confirmed by a deficiency of Tripeptidyl Peptidase 1 (TPP1) in white blood cells, or skin fibroblasts.
- 2. Genetic testing for mutations in the CLN2 disease gene or genetic testing has been requested and test results will be provided within 8 weeks.
- 3. Motor-Language (ML) score: Indicate the patient's ML score in the following table. Individual scores and total score for motor and language must be completed.

Date of assessment:

		ML	
Domain	Score	(Study 201 and 202)	Score
Motor	3	Grossly normal gait. No prominent ataxia,	
		no pathologic falls	
	2	Independent gait, as defined by ability to	
		walk without support for 10 steps. Will	
		have obvious instability, and may have	
		intermittent falls	
	1	Requires external assistance to walk, or	
		can crawl only	
	0	Can no longer walk or crawl	
Language	3	Apparently normal language. Intelligible	
		and grossly age appropriate. No decline	
		noted yet	
	2	Language has become recognizably	
		abnormal: some intelligible words, may	
		form short sentences to convey concepts,	
		requests, or needs. This score signifies a	
		decline from a previous level of ability	
		(from the individual maximum reached by	
		the child)	
	1	Hardly understandable. Few intelligible	
		words	
	0	No intelligible words or vocalizations	
		Total Score	

- 5. The patient does not have any of the conditions listed in the exclusion criteria in the CLN2 disease Guidelines.
- 6. I have advised the LSDP if the patient is participating in a clinical trial.

Data requirement checklist

- 7. I have provided a clinic letter outlining the patient's recent medical and surgical history and general description of their health status.
- 8. I have provided copies of all relevant reports and the completed Excel spreadsheet for CLN2 disease.

Treating physician's declaration

I confirm that:

I am the treating physician of the patient as stated in this form, and have relevant specialist registration. I hereby apply for Australian Government subsidised access to treatment for CLN2 disease through the LSDP on behalf of my patient.

I declare that:

- The information provided in this form is complete and correct.
- To the best of my knowledge, my patient is eligible to receive subsidised treatment for CLN2 disease through the LSDP in accordance with the Guidelines.
- I am aware that the patient must be an Australian citizen or permanent Australian resident who qualifies for Medicare.

I understand that:

- I have an ongoing obligation to ensure that my patient continues to meet the eligibility criteria to receive subsidised treatment through the LSDP.
- I have an ongoing obligation to report a sustained decline ≥2 points in the ML score to the Department over any continuous 48 week period during the course of their treatment to the Department.
- Making a false or misleading declaration is a serious offence and may lead to further investigations.
- I must submit a separate reapplication for subsidised treatment through the LSDP by 1 May each year if I wish for my patient to continue to receive subsidised treatment.

I agree that:

Treating physician's full name

If I become aware that my patient no longer meets the eligibility criteria for subsidised access to treatment through the LSDP at any time, I will notify the LSDP immediately.

Treating physician's full fiame	
Treating physician's signature	
Date	

Page 4 of 4 Version date: October 2024